Omega Healthcare Invest.

The share of Omega Healthcare Investors rose to a record high of $49.33 and is currently trading near that level, with a market capitalization of $15.37 billion. Over the past year the stock gained 40.49% and offers a dividend yield of 5.56%, with dividends paid for 24 consecutive years. For Q1 2026 the company reported revenue of $323 million, beating expectations, while earnings per share of $0.47 were slightly below forecasts. Analysts' reactions are mixed: UBS confirms » Więcej na de.investing.com

Omega Healthcare Investors names Matthew Gourmand effective Oct. 1, 2026 as CEO; he succeeds Taylor Pickett, who is retiring after 25 years. Neal Ballew will be promoted from chief accounting officer to CFO effective Aug. 1, 2026 and replaces Bob Stephenson, who is also retiring after 25 years. The board describes the changes as the result of a multi-year succession plan; under Pickett the portfolio grew to 1,124 facilities and market capitalization rose to over $15 billion. » Więcej na de.investing.com

Analysts from Wells Fargo, Truist and Scotiabank raised price targets on Omega Healthcare Investors while maintaining Equal Weight/Hold/Sector Perform ratings. Truist trimmed 2026–2027 normalized FFO forecasts slightly and firms caution that competition in healthcare REITs tempers near-term upside despite improving same-store NOI trends in senior housing. Omega remains focused on skilled nursing and assisted living financing, but analyst views keep the stock in a neutral stance. » Więcej na finance.yahoo.com

Shares of Omega Healthcare Investors climbed to an all‑time high of $46.38. For 2025 the stock was up 34.74% and offers a dividend yield of 5.9% after 24 consecutive years of payouts. The company beat Q4‑2025 expectations (EPS $0.55 vs. $0.49; revenue $319 million vs. $262.2 million), Cantor Fitzgerald raised its price target to $52, and InvestingPro rates the financial position as "EXCELLENT," with fair‑value estimates suggesting a slight undervaluation. » Więcej na de.investing.com

Omega Healthcare reported Q4 2025 EPS of $0.55 versus an expected $0.49 and revenue of $319 million compared with forecasts of $262.2 million. The stock rose 4.82% to $42.96 after the release; the company reduced interest-bearing liabilities by more than $700 million. For 2026, Omega expects adjusted FFO of $3.15–$3.25 per share and is targeting further growth through regional and segmented capital investments. » Więcej na de.investing.com